Merck KGaA names new life science chief; Clyde raises €2M; Reuters gives a thumbs-up to AstraZeneca;

@FierceBiotech: Galapagos' closely-watched rheumatoid arthritis drug filgotinib scores in PhIIb. Report | Follow @FierceBiotech

@JohnCFierce: Meanwhile, back in biotech boomland, Aduro prices at $17 a share. Over the range
$ADRO. Reuters story | Follow @JohnCFierce

> Merck KGaA has named Udit Batra as the new head of its life sciences division, following the $17 billion Sigma-Aldrich buyout. Story

> Clyde Biosciences has rounded up a £2 million Series A investment. The round was led by Epidarex Capital, with contributions from Scottish Enterprise's investment arm, the Scottish Investment Bank and Glasgow University Holdings. Release

> Senior Reuters writer Ben Hirschler gives AstraZeneca ($AZN) and CEO Pascal Soriot high marks for reorganizing the company as key franchises lose patent protection. Story

Medical Device News

@FierceMedDev: EarlySense nabs Mitsui as Japan partner, investor and ups financing to $25M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic joins St. Jude in leadless pacemaker market thanks to CE mark. Report | Follow @VarunSaxena2

@EmilyWFierce: Visual app acts as a "cheat sheet" for docs looking for a quick diagnosis. Wired story | Follow @EmilyWFierce

> Startup raises $4M for sterilization with vaporized hydrogen peroxide. More

> Baxter expanding its manufacturing plant in Arkansas amid preparations to spin off pharma biz. Story

Pharma News

@FiercePharma: ICYMI yesterday: Merck's Frazier joins top-paid pharma CEOs with a $25M package. Article | Follow @FiercePharma

@EricPFierce: Sounds like Walgreens would like to buy into another drug distributor like AmerisourceBergen. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: The coming generics threat to Pfizer's Viagra brand just got scarier. FiercePharmaMarketing report | Follow @CarlyHFierce

> Congress spurs feds to investigate sky-high generic drug prices. News

> Novartis has fresh data to support newly acquired CLL drug Arzerra. Article

> Onglyza's label should flag heart failure risks, FDA panel says. Story

Pharma Marketing News

> Eisai rejig means sales-force downsizing at a critical moment for Arena's Belviq. More

> Tech it out: Pfizer, AARP and UnitedHealthcare push innovation. Report

> J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1. More

> DTC ad viewers really do ask their doctors about new meds, survey finds. Story

> The coming generics threat to Pfizer's Viagra brand just got scarier. Article

Biotech Research News

> Focused on cell signaling, CHOP team preps for human mitochondrial drug study. Report

> UCLA team packs large cargo into cells. Item

> Scripps Parkinson's study points to a key enzyme as a potential drug target. More

> MIT team works on amping up a new approach to cancer immunotherapies. Story

> Chicago project highlights effects of an ancient Chinese cardio remedy. Article

Diagnostics News

> GE and Veracyte team up for disease diagnostic research collaboration. Item

> NIH awards $11M to develop tests for drug-resistant bacteria. Story

> FDA announces LuSys Labs' recall of its unapproved Ebola diagnostic. More

> Roche grabs CAPP Medical to gain ground in cancer Dx. News

> Biocartis joins forces with Microbiome for quick sepsis test. Article

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.